Molecular classification of acute myeloid leukemia: Are we there yet?

Journal of Clinical Oncology

Volumn 26, Issue 28, 2008, Pages 4539-4541

  Radich, Jerald P ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; TRANSCRIPTION FACTOR; WT1 PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; AUTOTRANSPLANTATION; CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; EDITORIAL; GENE MUTATION; GENETIC RISK; HUMAN; NEPHROBLASTOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, WILMS TUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; REMISSION INDUCTION; SIGNAL TRANSDUCTION;

EID: 53749102779     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.16.4293     Document Type: Editorial

References (28)

1. Byrd JC, Mrozek K, Dodge RK, et al: Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: Results from Cancer and Leukemia Group B (CALGB 8461). Blood 100:4325-4336, 2002
2. Meshinchi S, Stirewalt DL, Alonzo TA, et al: Activating mutations of RTK/ras signal transduction pathway in pediatric acute myeloid leukemia. Blood 102:1474-1479, 2003
3. Stirewalt DL, Kopecky KJ, Meshinchi S, et al: FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. Blood 97:3589-3595, 2001
4. Neubauer A, Dodge RK, George SL, et al: Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 83:1603-1611, 1994
5. Radich JP, Kopecky KJ, Willman CL, et al: N-ras mutations in adult de novo acute myelogenous leukemia: Prevalence and clinical significance. Blood 76:801-807, 1990
6. Kottaridis PD, Gale RE, Frew ME, et al: The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759, 2001
7. Meshinchi S, Alonzo TA, Stirewalt DL, et al: Clinical implications of FLT3 mutations in pediatric AML. Blood 108:3654-3661, 2006
8. Yamamoto Y, Kiyoi H, Nakano Y, et al: Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434-2439, 2001
9. Gale RE, Green C, Allen C, et al: The impact of FLT3 internal tandem duplication mutant level, number, size and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 111:2776-2784, 2008
10. Thiede C, Steudel C, Mohr B, et al: Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335, 2002
11. Whitman SP, Archer KJ, Feng L, et al: Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A cancer and leukemia group B study. Cancer Res 61:7233-7239, 2001
12. Döhner K, Schlenk RF, Habdank M, et al: Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: Interaction with other gene mutations. Blood 106:3740-3746, 2005
13. Falini B, Mecucci C, Tiacci E, et al: Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 352:254-266, 2005
14. Schnittger S, Schoch C, Kern W, et al: Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733-3739, 2005
15. Thiede C, Koch S, Creutzig E, et al: Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 107:4011-4020, 2006
16. Bullinger L, Dohner K, Bair E, et al: Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350:1605-1616, 2004
17. Wilson CS, Davidson GS, Martin SB, et al: Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108:685-696, 2006
18. Paschka P, Marcucci G, Ruppert AS, et al: Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B Study. J Clin Oncol 26:4595-4602, 2008
19. Yang L, Han Y, Suarez Saiz F, et al: A tumor suppressor and oncogene: The WT1 story. Leukemia 21:868-876, 2007
20. Bergmann L, Miething C, Maurer U, et al: High levels of Wilms' tumor gene (wt1) mRNA in acute myeloid leukemias are associated with a worse long-term outcome. Blood 90:1217-1225, 1997
21. King-Underwood L, Pritchard-Jones K: Wilms' tumor (WT1) gene mutations occur mainly in acute myeloid leukemia and may confer drug resistance. Blood 91:2961-2968, 1998
22. Weisser M, Kern W, Rauhut S, et al: Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia. Leukemia 19:1416-1423, 2005
23. Summers K, Stevens J, Kakkas I, et al: Wilms' tumor 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 21:550-551; aut, 2007
24. Fröhling S, Schlenk RF, Stolze I, et al: CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations. J Clin Oncol 22:624-633, 2004
25. Marcucci G, Baldus CD, Ruppert AS, et al: Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: A Cancer and Leukemia Group B study. J Clin Oncol 23:9234-9242, 2005
26. Marcucci G, Mrózek K, Ruppert AS, et al: Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B study. J Clin Oncol 23:5705-5717, 2005
27. Neubauer A, Maharry K, Mrózek K, et al: Patients with acute myeloid leukemia and RAS mutations benefit most from postremission treatment with high-dose cytarabine: A Cancer and Leukemia Group B study. J Clin Oncol 26:4603-4609, 2008
28. Byrd JC, Ruppert AS, Mrozek K, et al: Repetitive cycles of high-dose cytarabine benefit patients with acute myeloid leukemia and inv(16)(p13q22) or t(16;16)(p13;q22): Results from CALGB 8461. J Clin Oncol 22:1087-1094, 2004